Angiotech up after Taxus approval

Angiotech Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI) gained C$0.57 (43%) to C$1.89 on Wednesday after FDA approved the Taxus Liberte Atom paclitaxel-eluting coronary stent system from Boston Scientif...